New Results
Nafamostat-interferon-alpha combination suppresses SARS-CoV-2 infection by targeting cooperatively host TMPRSS2 in vitro and in vivo
Aleksandr Ianevski, Rouan Yao, Hilde Lysvand, Gunnveig Grødeland, Nicolas Legrand, Valentin Oksenych, Eva Zusinaite, Tanel Tenson, Magnar Bjørås, View ORCID ProfileDenis E. Kainov
doi: https://doi.org/10.1101/2021.06.16.448653
Aleksandr Ianevski
1Department of Clinical and Molecular Medicine (IKOM), Norwegian University of Science and Technology, 7028, Trondheim, Norway
Rouan Yao
1Department of Clinical and Molecular Medicine (IKOM), Norwegian University of Science and Technology, 7028, Trondheim, Norway
Hilde Lysvand
1Department of Clinical and Molecular Medicine (IKOM), Norwegian University of Science and Technology, 7028, Trondheim, Norway
Gunnveig Grødeland
2Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, 0372, Oslo, Norway
3Institute of Clinical Medicine (KlinMed), University of Oslo, 0318, Oslo, Norway
4Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital Rikshospitalet, 0372, Oslo, Norway
Nicolas Legrand
5Oncodesign, 25 Avenue du Québec, 91140 Villebon Sur Yvette, France
Valentin Oksenych
1Department of Clinical and Molecular Medicine (IKOM), Norwegian University of Science and Technology, 7028, Trondheim, Norway
Eva Zusinaite
6Institute of Technology, University of Tartu, 50411 Tartu, Estonia
Tanel Tenson
6Institute of Technology, University of Tartu, 50411 Tartu, Estonia
Magnar Bjørås
1Department of Clinical and Molecular Medicine (IKOM), Norwegian University of Science and Technology, 7028, Trondheim, Norway
Denis E. Kainov
1Department of Clinical and Molecular Medicine (IKOM), Norwegian University of Science and Technology, 7028, Trondheim, Norway
6Institute of Technology, University of Tartu, 50411 Tartu, Estonia
7Institute for Molecular Medicine Finland, FIMM, University of Helsinki, 00014, Helsinki, Finland
Article usage
Posted June 30, 2021.
Nafamostat-interferon-alpha combination suppresses SARS-CoV-2 infection by targeting cooperatively host TMPRSS2 in vitro and in vivo
Aleksandr Ianevski, Rouan Yao, Hilde Lysvand, Gunnveig Grødeland, Nicolas Legrand, Valentin Oksenych, Eva Zusinaite, Tanel Tenson, Magnar Bjørås, Denis E. Kainov
bioRxiv 2021.06.16.448653; doi: https://doi.org/10.1101/2021.06.16.448653
Nafamostat-interferon-alpha combination suppresses SARS-CoV-2 infection by targeting cooperatively host TMPRSS2 in vitro and in vivo
Aleksandr Ianevski, Rouan Yao, Hilde Lysvand, Gunnveig Grødeland, Nicolas Legrand, Valentin Oksenych, Eva Zusinaite, Tanel Tenson, Magnar Bjørås, Denis E. Kainov
bioRxiv 2021.06.16.448653; doi: https://doi.org/10.1101/2021.06.16.448653
Subject Area
Subject Areas
- Biochemistry (11730)
- Bioengineering (8743)
- Bioinformatics (29179)
- Biophysics (14964)
- Cancer Biology (12080)
- Cell Biology (17399)
- Clinical Trials (138)
- Developmental Biology (9417)
- Ecology (14174)
- Epidemiology (2067)
- Evolutionary Biology (18294)
- Genetics (12233)
- Genomics (16791)
- Immunology (11858)
- Microbiology (28051)
- Molecular Biology (11575)
- Neuroscience (60919)
- Paleontology (451)
- Pathology (1870)
- Pharmacology and Toxicology (3238)
- Physiology (4955)
- Plant Biology (10422)
- Synthetic Biology (2881)
- Systems Biology (7338)
- Zoology (1650)